June 2020
Volume 61, Issue 7
ARVO Annual Meeting Abstract  |   June 2020
Progression of partial posterior vitreous detachment over time
Author Affiliations & Notes
  • Eileen Hwang
    University of Utah / Moran Eye Center, Utah, United States
  • Jessica Kraker
    ophthalmology, Medical College of Wisconsin/ Froedtert Eye Instit, Salt Lake City, Utah, United States
  • Elizabeth Koller
    ophthalmology, Medical College of Wisconsin/ Froedtert Eye Instit, Salt Lake City, Utah, United States
  • Footnotes
    Commercial Relationships   Eileen Hwang, Alcon (R), Katalyst (R), Spark Therapeutics (R); Jessica Kraker, None; Elizabeth Koller, None
  • Footnotes
    Support  Vitreoretinal surgery foundation, Research to Prevent Blindness, NIH EY0148000
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 4821. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Eileen Hwang, Jessica Kraker, Elizabeth Koller; Progression of partial posterior vitreous detachment over time. Invest. Ophthalmol. Vis. Sci. 2020;61(7):4821.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Posterior vitreous detachment (PVD) progresses from stage 0 (no PVD), through stages 1 to 3 of partial PVD, and finally to stage 4 (complete PVD). Cross-sectional studies demonstrated that PVD stage increases with age and average vitreomacular adhesion area (VMAA) decreases. However, longitudinal studies capturing changes in individual eyes are lacking.

Methods : We retrospectively evaluated PVD stage and VMAA in asymptomatic eyes of retina clinic patients who underwent repeated optical coherence tomography (OCT) screening for high-risk medication use or isolated retinal disease in the fellow eye.

Results : We evaluated 101 eyes of 101 patients (71 female, 30 male; average age 50 years). 76 eyes remained in the same stage over the entire follow up period (average length 4.7 years). 23 eyes progressed from a lower stage to a higher stage. The data were used to create a statistical model to predict time to convert from stages 0-3 to stage 4 PVD. At age 30, time to convert to stage 4 was predicted to be 26 years; at age 40, it was 16 years; at age 50, it was 9 years; and at age 60, it was 8 years. VMAA was assessed in repeated scans from 37 eyes with stage 1 partial PVD. The rate of change in VMAA was similar across all subjects. The average population level yearly decline in VMAA was 0.13 mm2.

Conclusions : Individuals vary in the age at which they progress to complete PVD, but the rate of VMAA change is similar between individuals.

This is a 2020 ARVO Annual Meeting abstract.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.